Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients



Status:Completed
Conditions:Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:10/7/2018
Start Date:June 20, 2012
End Date:February 5, 2018

Use our guide to learn which trials are right for you!

A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma

The primary objective of this study was to compare progression-free survival in patients with
multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus
dexamethasone or bortezomib plus dexamethasone.


Inclusion Criteria:

1. Multiple myeloma with relapsing or progressing disease at study entry.

2. Patients must have evaluable multiple myeloma with, at least one of the following
(assessed within 21 days prior to randomization):

- Serum M-protein ≥ 0.5 g/dL, or

- Urine M-protein ≥ 200 mg/24 hour, or

- In patients without detectable serum or urine M-protein, serum free light chain
(SFLC) > 100 mg/L (involved light chain) and an abnormal serum kappa/lamda ratio,
or

- For immunoglobulin (Ig) A patients whose disease can only be reliably measured by
serum quantitative immunoglobulin (qIgA) ≥ 750 mg/dL (0.75 g/dL).

3. Patients must have documented at least partial response (PR) to at least 1 line of
prior therapy. PR documentation can be based on Investigator assessment.

4. Received 1, but no more than 3 prior treatment regimens or lines of therapy for
multiple myeloma. (Induction therapy followed by stem cell transplant and
consolidation/maintenance therapy will be considered as one line of therapy).

5. Prior therapy with Velcade is allowed as long as the patient had at least a PR to
prior Velcade therapy, was not removed from Velcade therapy due to toxicity, and will
have at least a 6 month Velcade treatment-free interval from last dose received until
first study treatment. (Patients may receive maintenance therapy with drugs that are
not in the proteasome inhibitor class during this 6 month Velcade treatment-free
interval).

6. Prior therapy with carfilzomib is allowed as long as the patient had at least a PR to
prior carfilzomib therapy, was not removed from carfilzomib therapy due to toxicity,
and had at least a 6-month carfilzomib treatment-free interval from last dose received
until first study treatment. (Patients may receive maintenance therapy with drugs that
are not in the proteasome inhibitor class during this 6 month carfilzomib
treatment-free interval). The exception to this is patients randomized or previously
randomized in any other Onyx-Sponsored Phase 3 trial.

7. Males and females ≥ 18 years of age.

8. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.

9. Adequate hepatic function within 21 days prior to randomization, with bilirubin < 1.5
times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) < 3 times the ULN.

10. Left ventricular ejection fraction (LVEF) ≥ 40%.

11. Absolute neutrophil count (ANC) ≥ 1000/mm³ within 21 days prior to randomization.
Screening ANC should be independent of growth factor support for ≥ 1 week.

12. Hemoglobin ≥ 8.0 g/dL within 21 days prior to randomization. Use of erythropoietic
stimulating factors and red blood cell (RBC) transfusions per institutional guidelines
is allowed, however most recent RBC transfusion may not have been done within 7 days
prior to obtaining screening hemoglobin.

13. Platelet count ≥ 50,000/mm³ (≥ 30,000/mm³ if myeloma involvement in the bone marrow is
> 50%) within 21 days prior to randomization. Patients should not have received
platelet transfusions for at least 1 week prior to obtaining the screening platelet
count.

14. Calculated or measured creatinine clearance (CrCl) of ≥ 15 mL/min within 21 days prior
to randomization. Calculation should be based on standard formula such as the
Cockcroft and Gault:

[(140 - Age) x Mass (kg) / (72 x Creatinine mg/dL)]; multiply result by 0.85 if
female.

15. Written informed consent in accordance with federal, local, and institutional
guidelines.

16. Female patients of child-bearing potential (FCBP) must have a negative serum pregnancy
test within 21 days prior to randomization and agree to use an effective method of
contraception during and for 3 months following last dose of drug (more frequent
pregnancy tests may be conducted if required per local regulations). FCBP is defined
as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral
oophorectomy or 2) has not been naturally postmenopausal (amenorrhea following cancer
therapy does not rule out childbearing potential) for at least 12 consecutive months
(i.e., has had menses at any time in the preceding 12 consecutive months).

17. Male patients must use an effective barrier method of contraception during study and
for 3 months following the last dose if sexually active with a FCBP.

Exclusion Criteria:

1. Multiple Myeloma of IgM subtype.

2. Glucocorticoid therapy (prednisone > 30 mg/day or equivalent) within 14 days prior to
randomization.

3. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and
skin changes).

4. Plasma cell leukemia or circulating plasma cells ≥ 2 × 10^9/L.

5. Waldenstrom's Macroglobulinemia.

6. Patients with known amyloidosis.

7. Chemotherapy with approved or investigational anticancer therapeutics within 21 days
prior to randomization.

8. Patients randomized or previously randomized in any other Onyx-Sponsored Phase 3
trial.

9. Focal radiation therapy within 7 days prior to randomization. Radiation therapy to an
extended field involving a significant volume of bone marrow within 21 days prior to
randomization (i.e., prior radiation must have been to less than 30% of the bone
marrow).

10. Immunotherapy within 21 days prior to randomization.

11. Major surgery (excluding kyphoplasty) within 28 days prior to randomization.

12. Active congestive heart failure (New York Heart Association [NYHA] Class III to IV),
symptomatic ischemia, or conduction abnormalities uncontrolled by conventional
intervention. Myocardial infarction within four months prior to randomization.

13. Acute active infection requiring systemic antibiotics, antiviral (except antiviral
therapy directed at hepatitis B) or antifungal agents within 14 days prior to
randomization.

14. Known human immunodeficiency (HIV) seropositive, hepatitis C infection, and/or
hepatitis B (except for patients with hepatitis B surface antigen [SAg] or core
antibody receiving and responding to antiviral therapy directed at hepatitis B: these
patients are allowed).

15. Patients with known cirrhosis.

16. Second malignancy within the past 3 years except:

- adequately treated basal cell or squamous cell skin cancer

- carcinoma in situ of the cervix

- prostate cancer < Gleason score 6 with stable prostate-specific antigen (PSA)
over 12 months

- breast carcinoma in situ with full surgical resection

- treated medullary or papillary thyroid cancer

17. Patients with myelodysplastic syndrome.

18. Significant neuropathy (Grades 3 to 4, or Grade 2 with pain) within 14 days prior to
randomization.

19. Female patients who are pregnant or lactating.

20. Known history of allergy to Captisol(a cyclodextrin derivative used to solubilize
carfilzomib).

21. Patients with hypersensitivity to carfilzomib, Velcade, boron, or mannitol.

22. Patients with contraindication to dexamethasone.

23. Contraindication to any of the required concomitant drugs or supportive treatments,
including hypersensitivity to antiviral drugs, or intolerance to hydration due to
preexisting pulmonary or cardiac impairment.

24. Ongoing graft-vs-host disease.

25. Patients with pleural effusions requiring thoracentesis or ascites requiring
paracentesis within 14 days prior to randomization.
We found this trial at
28
sites
2220 Pierce Ave
Nashville, Tennessee 37232
615-936-8422
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
3550 Jerome Avenue
Bronx, New York 10467
(718) 920-4321
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
?
mi
from
Bronx, NY
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Atlanta, Georgia 30322
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
6410 Rockledge Dr #660
Bethesda, Maryland 20817
(301) 571-0019
Center for Cancer & Blood Disorders Widely recognized for its compassionate, expert care, the Center...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Burbank, California 91505
?
mi
from
Burbank, CA
Click here to add this to my saved trials
Camperdown, New South Wales 2050
?
mi
from
Camperdown,
Click here to add this to my saved trials
4875 Higbee Ave NW
Canton, Ohio 44718
330-492-3345
Gabrail Cancer Center Since 1990, Gabrail Cancer Center has built a national reputation for excellence...
?
mi
from
Canton, OH
Click here to add this to my saved trials
2139 Auburn Ave
Cincinnati, Ohio 45219
(513) 585-2000
The Christ Hospital For more than 120 years, The Christ Hospital has been a leader...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
1721 East 19th Ave., Suite #200 & #300
Denver, Colorado 80218
720-754-4800
Colorado Blood Cancer Institute When patients come to the Colorado Blood Cancer Institute, the entire...
?
mi
from
Denver, CO
Click here to add this to my saved trials
Greenville, South Carolina 29605
?
mi
from
Greenville, SC
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Indianapolis, Indiana 46260
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Kansas City, Missouri 64152
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
La Jolla, California
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
757 Westwood Plaza
Los Angeles, California 90024
(310) 825-9111
UCLA Medical Center Founded in 1955, UCLA Medical Center became Ronald Reagan UCLA Medical Center...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Melbourne, Florida
?
mi
from
Melbourne, FL
Click here to add this to my saved trials
New York, New York 10021
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10021
?
mi
from
New York, NY
Click here to add this to my saved trials
4800 Friendship Ave
Pittsburgh, Pennsylvania 15224
(412) 578-5000
Western Pennsylvania Hospital Featuring 308 private patient beds, West Penn Hospital has served Bloomfield and...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Rockville, Maryland 20850
?
mi
from
Rockville, MD
Click here to add this to my saved trials
Salt Lake City, Utah 84132
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Santa Maria, California 93454
?
mi
from
Santa Maria, CA
Click here to add this to my saved trials
2401 S. 31st Street
Temple, Texas 76508
254-724-2111
Scott & White Memorial Hospital When Arthur C. Scott, MD, and Raleigh R. White Jr.,...
?
mi
from
Temple, TX
Click here to add this to my saved trials
West Palm Beach, Florida 33401
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials